Abexinostat
- Generic Name
- Abexinostat
- Drug Type
- Small Molecule
- Chemical Formula
- C21H23N3O5
- CAS Number
- 783355-60-2
- Unique Ingredient Identifier
- IYO470654U
- Background
Abexinostat has been used in trials studying the treatment of Sarcoma, Lymphoma, Leukemia, Lymphocytic, and Hodgkin Disease, among others. It is a novel, broad-spectrum hydroxamic acid-based inhibitor of histone deacetylase (HDAC) with potential antineoplastic activity.
PCI-24781 in Combination With Doxorubicin to Treat Sarcoma
- First Posted Date
- 2009-12-09
- Last Posted Date
- 2024-03-12
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT01027910
- Locations
- ๐บ๐ธ
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
๐บ๐ธMassachusetts General Hospital, Boston, Massachusetts, United States
Study of the Safety and Tolerability of PCI-24781 in Patients With Lymphoma
- First Posted Date
- 2008-07-30
- Last Posted Date
- 2014-04-07
- Lead Sponsor
- Pharmacyclics LLC.
- Target Recruit Count
- 55
- Registration Number
- NCT00724984
- Locations
- ๐บ๐ธ
University of Vermont and Fletcher Allen Health Care, Burlington, Vermont, United States
๐บ๐ธWashington University School of Medicine, St. Louis, Missouri, United States
๐บ๐ธUniversity of California, San Francisco, San Francisco, California, United States
Study of the Safety and Tolerability of Oral Capsule Form of PCI-24781 in Advanced Cancer Patients
- Conditions
- Neoplasms by SiteLymphoma, Non-hodgkinHodgkin DiseaseMultiple MyelomaLeukemia, Lymphocytic, Chronic
- Interventions
- First Posted Date
- 2007-11-21
- Last Posted Date
- 2011-09-28
- Lead Sponsor
- Pharmacyclics LLC.
- Target Recruit Count
- 36
- Registration Number
- NCT00562224
- Locations
- ๐บ๐ธ
MD Anderson Cancer Center, Houston, Texas, United States
๐บ๐ธUniversity of Chicago, Chicago, Illinois, United States
๐บ๐ธCalifornia Cancer Care, Greenbrae, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.